Poolbeg Pharma PLC Announces Voluntary Delisting From OTCQB Market
Poolbeg Pharma PLC Announces Change of Registered Address
Poolbeg Pharma PLC Announces Result of AGM
Poolbeg Pharma PLC Announces Annual Report & AGM Notice
Poolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in USA
Poolbeg Pharma PLC Announces Appointment of Joint Broker
Favourable Signals For Poolbeg Pharma: Numerous Insiders Acquired Stock
Poolbeg Pharma PLC Announces POLB 001 US Patent Update
Poolbeg Pharma PLC Announces Director/PDMR Shareholding
Poolbeg Pharma Chair Discusses Shift to Executive Role; HVIVO Share Sale
Poolbeg Pharma PLC Announces Director Share Purchase
Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP
Poolbeg Pharma PLC Announces Market Opportunity for POLB 001 for CRS
Poolbeg Pharma PLC Announces Further Data Shows POLB001 Potential in Cancer CRS
Poolbeg Pharma PLC Announces RSV AI Drug Candidate Analysis Update
Poolbeg Pharma PLC Announces POLB 001 Data Presented at ASH
Poolbeg Pharma PLC Announces Directorate Change
Poolbeg Pharma PLC Announces Immunomodulator II Patent Granted in Japan
Poolbeg Pharma PLC Announces POLB 001 LPS Trial Data to Be Presented at IUIS
Former Amryt Pharma Leadership Team Join Poolbeg